Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-3 in Advanced Colorectal Cancer
NCT05999396Phase 1Recruiting
- Sponsor
- German Cancer Research Center
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CC-3 in colorectal cancer (CRC), sponsored by German Cancer Research Center. Primary endpoints: Incidence and Severity of Adverse Events, Blood Chemistry - Transaminases and 6 more. Started Jan 2024; status: recruiting.
02
Drugs
CC-3
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05999396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999396.